An Open-Label Phase 1 Study to Evaluate the Safety of ATA188 in Subjects with Progressive and Relapsing-Remitting Multiple Sclerosis

Recruiting
99 years or below
All
Phase 1

Brief description of study

The purpose of the study is to determine the safety and tolerability of ATA188 in subjects with progressive forms of multiple sclerosis. Up to 42 male or female subjects with progressive forms of MS and 42 subjects with Relapsing-Remitting MS will be enrolled. The subjects will be randomized to receive study drug or placebo and will receive 2 treatment cycles followed by 11 monthly follow-up visits.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: TBD
  • Age: 99 years or below
  • Gender: All
Updated on 10 Jul 2019. Study ID: 830135

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.